Visceral leishmaniasis is characterized by severe immune suppression of the host. This suppression of the host immune system is primarily mediated by the immunosuppressive cytokine Interleukin-10 (IL-10), whose levels are significantly upregulated during leishmaniasis. This immune suppression is reflected at the level of T-cell dysfunction and abrogation of leishmaniacidal molecules along with a dampened Th1 cytokine response. In the present study, we showed in vivo neutralization of IL-10 by administration of anti IL-10 monoclonal antibodies (mAb) could confer protection against leishmanial pathogenesis. This protective response was primarily mediated by a strong induction of T cell proliferation along with a Th1 biased cytokine response which was further aided by the generation of, leishmanicidal molecules, nitric oxide.
Download full-text PDF |
Source |
---|
Am J Trop Med Hyg
December 2024
Graduate Program in Biological Sciences, Center for Research in Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil.
PLoS Negl Trop Dis
December 2024
Genômica Funcional de Parasitos, Instituto René Rachou-Oswaldo Cruz Foundation, Belo Horizonte, Minas Gerais, Brazil.
Background: Visceral leishmaniasis (VL) is an infectious parasitic disease caused by the species Leishmania (Leishmania) infantum in the Mediterranean Basin, the Middle East, Central Asia, South America, and Central America, and Leishmania (Leishmania) donovani in Asia and Africa. VL represents the most severe and systemic form of the disease and is fatal if left untreated. Vaccines based on chimeric or multiepitope antigens hold significant potential to induce a highly effective and long-lasting immune response against infections by these parasites.
View Article and Find Full Text PDFSci Rep
December 2024
Department of Statistics, College of Natural and Computational Sciences, Gambella University, Gambella, Ethiopia.
Visceral leishmaniasis (VL) is a neglected tropical disease that mostly affects the working-class and impoverished segments of society, having a significant negative effect on the economic development of the affected nation. While anti-leishmanial medications lower mortality among VL patients, patients may still die or require more time to recover (TTR) while receiving treatment. In this regard, there are limited studies in Ethiopia.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
Zoonoses Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Background: COVID-19 is a pandemic involving coinfection with other opportunistic microorganisms, including parasites such as Leishmania infantum. The present study aimed to determine the frequency of L. infantum infection and its role in disease and mortality among symptomatic COVID-19 patients in comparison with the non-COVID-19 control group in the endemic area of visceral leishmaniasis (VL) in Iran.
View Article and Find Full Text PDFParasit Vectors
December 2024
College of Public Health, University of Iowa, Iowa City, IA, USA.
Background: Visceral leishmaniosis (VL) is the most severe form of human leishmaniosis, with an estimated 95% case fatality if left untreated. Dogs act as peridomestic reservoir hosts for the protozoan parasite Leishmania infantum, a causative agent for human leishmaniosis, endemic throughout the Mediterranean basin. To assure consistent and accurate surveillance of canine infection and prevent transmission to people, consistent diagnosis of canine L.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!